Neurontin (Gabapentin) 100–800 mg Capsules and Tablets: Prescription Calcium Channel Alpha-2-Delta Ligand for Postherpetic Neuralgia, Partial Seizures, and Neuropathic Pain

Reviewed by the Lucas Clinic Medical Team | Updated May 2026

Gabapentin (Neurontin) is a structural analogue of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) — but despite its name, gabapentin does not act on GABA receptors and is not a GABA agonist. Its primary mechanism of action involves binding to the alpha-2-delta (α2δ) subunit of voltage-gated calcium channels, particularly in dorsal root ganglia and spinal cord neurons involved in pain transmission. This binding reduces calcium influx at presynaptic terminals, thereby decreasing the release of excitatory neurotransmitters (glutamate, substance P, calcitonin gene-related peptide) at synapses in pain pathways. This mechanism accounts for its efficacy in neuropathic pain states characterised by abnormal neuronal hyperexcitability.

Gabapentin has two FDA-approved indications: postherpetic neuralgia (PHN — persistent pain after shingles) and adjunctive therapy for partial-onset seizures in adults and children (≥3 years). However, gabapentin is among the most widely used off-label medications in US clinical practice. Major off-label uses include: diabetic peripheral neuropathy (DPN), fibromyalgia, generalised anxiety disorder, alcohol withdrawal (hospitalised patients), chemotherapy-induced peripheral neuropathy, restless legs syndrome (though ropinirole and pramipexole are preferred), chronic low back pain (with mixed evidence), and various other chronic pain conditions. The breadth of off-label prescribing reflects the perception of gabapentin as a "relatively safe" drug, though this perception has been challenged by escalating evidence of misuse, abuse potential, dependence, and overdose — particularly in combination with opioids.

What Is Neurontin (Gabapentin)?

Gabapentin's absorption from the gastrointestinal tract is dose-dependent and saturable — an unusual pharmacokinetic property meaning that as the dose increases, the percentage absorbed actually decreases (bioavailability ranges from approximately 60% at 300 mg TID to 27% at 1600 mg TID). This saturable absorption is why gabapentin must be taken in divided doses (typically three times daily for IR formulations) rather than once or twice daily — a single large dose does not achieve proportionally higher blood levels. This is also why gabapentin doses are titrated incrementally. Gabapentin enacarbil (Horizant) is a prodrug extended-release formulation that improves bioavailability by avoiding saturable absorption — it is FDA-approved for restless legs syndrome and PHN as a twice-daily formulation. Gabapentin is renally cleared with no hepatic metabolism — dose adjustment is required for all patients with impaired renal function (reduced creatinine clearance).

Growing concerns about gabapentin misuse and dependence have led to its scheduling as a controlled substance (Schedule V) in several US states including Kentucky, Tennessee, Michigan, Virginia, and others. In the UK, gabapentin was reclassified as a Class C controlled substance (Schedule 3) in 2019, requiring mandatory prescription documentation. The concern is particularly about gabapentin use alongside opioids — studies show dramatically increased overdose risk (respiratory depression) when gabapentin and opioids are co-administered. Patients on both gabapentin and opioids require careful monitoring and should be counselled about the combination's respiratory risks.

Prescription vs. Over-the-Counter Status

Gabapentin is a prescription-only medication in all US states and internationally. In states that schedule gabapentin as Schedule V controlled substance, additional prescription and dispensing requirements apply (e.g., no refills without new prescription in some states, mandatory PDMP reporting). There is no over-the-counter gabapentin available. The prescription requirement for gabapentin reflects the complexity of dosing titration, the need for renal function monitoring, the drug interaction profile, and the increasing recognition of misuse and dependence potential. Prescribers should periodically reassess the need for ongoing gabapentin therapy, particularly in patients on concurrent opioids or in patients without a clear FDA-approved indication.

Available Strengths and Forms

Neurontin (gabapentin IR) capsules and tablets: 100 mg capsules, 300 mg capsules, 400 mg capsules, 600 mg tablets, 800 mg tablets. Also available as oral solution 250 mg/5 mL.

Standard dosing for postherpetic neuralgia: Day 1: 300 mg once; Day 2: 300 mg twice daily; Day 3 onwards: 300 mg three times daily (TID). Titrate as tolerated to 1800–3600 mg/day in three divided doses over several weeks.

For diabetic neuropathy (off-label): similar titration, effective range typically 900–3600 mg/day TID.

For partial seizures: starting dose 300 mg TID; titrate to 900–1800 mg/day (max 2400 mg/day in children, up to 3600 mg/day in adults).

Horizant (gabapentin enacarbil ER): 300 mg and 600 mg extended-release tablets; approved for RLS (600 mg once daily at 5 PM) and PHN (600 mg twice daily). Must be swallowed whole with food — Do not cut, crush, or chew.

Generic gabapentin is widely available in all IR strengths at substantially lower cost than branded Neurontin.

Price of Neurontin / Gabapentin

Generic gabapentin is one of the least expensive prescription medications available. At standard doses (300 mg TID = 90 capsules/month), generic gabapentin 300 mg costs approximately $10–$20/month at most US pharmacies with GoodRx or generic discount pricing. Even at higher doses (600 mg TID = 180 tablets/month), generic gabapentin typically costs $20–$40/month. Branded Neurontin is rarely used due to cost relative to generics. Horizant (gabapentin enacarbil) has a higher cost profile — approximately $200–$400+/month — as it remains branded. Insurance coverage for gabapentin is generally straightforward for FDA-approved indications; prior authorisation may be required for some off-label uses.

Frequently Asked Questions

Why does gabapentin need to be taken three times a day?

Gabapentin's absorption from the gut is limited by saturable transport — a carrier-mediated process that becomes saturated at higher individual doses. Unlike most drugs where doubling the dose roughly doubles blood levels, gabapentin's bioavailability decreases at higher single doses: a 300 mg dose achieves approximately 60% absorption, while a 1600 mg dose achieves only about 27% absorption of that amount. The practical consequence is that to achieve therapeutic drug levels throughout the day, gabapentin must be dosed three times daily (or more frequently) for immediate-release formulations — large single doses do not compensate for this saturable absorption ceiling. The extended-release formulations (Horizant) use a prodrug mechanism (gabapentin enacarbil) to bypass this limitation, allowing twice-daily dosing with more consistent blood levels.

Is gabapentin addictive?

Gabapentin has historically been considered low-risk with respect to dependence, partly leading to its widespread off-label prescribing. However, emerging evidence has substantially revised this view. Physical dependence occurs with regular use — abrupt discontinuation causes withdrawal symptoms including anxiety, agitation, tremor, autonomic instability, insomnia, and in severe cases seizures. Patients must never stop gabapentin abruptly after prolonged use; doses must be tapered gradually under medical supervision. Additionally, gabapentin misuse and recreational use have been increasingly documented — particularly in individuals with substance use disorders, who report euphoric or potentiating effects (especially when combined with opioids, benzodiazepines, or alcohol). The combination of gabapentin with opioids creates disproportionately elevated overdose risk (approximately 50% increased risk of opioid overdose death in studies). This evidence has driven its scheduling as a controlled substance in several US states and in the UK.

How should gabapentin be dosed in patients with kidney disease?

Gabapentin is eliminated entirely by renal clearance (kidneys). Unlike most drugs that undergo hepatic metabolism, gabapentin is not metabolised — it is excreted unchanged in urine. Renal impairment therefore directly reduces its clearance, causing drug accumulation unless doses are reduced. Dose adjustment must be based on creatinine clearance (CrCl): CrCl ≥60 mL/min: standard dosing (up to 3600 mg/day TID). CrCl 30–59 mL/min: maximum 1400 mg/day in two divided doses. CrCl 15–29 mL/min: maximum 700 mg/day in a single daily dose. CrCl <15 mL/min: 300 mg every other day, or less. Patients on haemodialysis require supplemental post-dialysis doses because gabapentin is efficiently dialysed. Renal function should be checked before starting gabapentin and monitored during treatment, particularly in elderly patients in whom renal function often declines with age.

← Back to Nerve Pain Medications